Biopharma AI
By
Will LabGenius Therapeutics and Sanofi’s Second AI-Powered Alliance Accelerate the Next Wave of Antibody and NANOBODY® Innovation in Inflammatory Diseases?
Key Highlights / Executive Takeaways: • Expanded collaboration deepens trust between LabGenius Therapeutics and Sanofi, reinforcing AI/ML as…
Can Phare Bio and Basilea’s AI-Driven Alliance Redefine Antibiotic Discovery and Change the Fight Against Drug-Resistant Infections Worldwide?
Executive Takeaways: • First-of-its-kind partnership aligns AI-driven antibiotic design directly with patient-centric target product profiles, setting a new…
FDA Qualifies First AI Drug Development Tool, Will Be Used in ‘MASH’ Clinical Trials to Accelerate Liver Disease Drug Development
The U.S. Food and Drug Administration (FDA) has qualified AIM-NASH, the first AI-based tool designed to assist doctors…
How Novartis and Relation Therapeutics’ $1.7 Billion AI Collaboration Redefine Drug Discovery Success Rates in Immunology, Atopic Diseases?
Key Highlights: • AI-driven, patient-derived target discovery emerges as a new gold standard for reducing late-stage clinical failures•…
Will AI-Powered Prior Authorization Change How Medicare Care Is Delivered?
December 2025 — Medicare is preparing to introduce artificial intelligence–driven prior authorization reviews for certain medical services beginning…
How Is Senhwa Biosciences Using AI and Strategic Collaborations to Shape the Next Generation of Immuno-Oncology?
TAIPEI and SAN DIEGO — Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on first-in-class therapies for oncology,…
